(Epratuzumab)Biosimilar Reference Antibody-GS40236

货号：GS40236

Epratuzumab (development code hLL2) is a humanized monoclonal IgG1 antibody developed for the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE). It functions as a B-cell modulating therapy. Unlike B-cell depletion agents such as rituximab (anti-CD20), epratuzumab is considered a B-cell immunomodulator. It binds to a specific surface antigen on B cells, leading to the reduction of circulating B cells through mechanisms that appear to involve antibody-dependent cellular cytotoxicity (ADCC) and, more distinctly, the induction of tolerogenic signaling. This results in a more moderate, non-lytic modulation of B-cell activity and migration rather than profound depletion, aiming to dampen the abnormal autoimmune response without causing extensive immunosuppression.